Company: Fischer Medical Ventures Limited
Announcement Date: 14 August 2025

Key Financial Metrics (Q1 FY26 ended 30 June 2025):

• Standalone:
  • Revenue from operations: ₹454.23 Lakhs (down QoQ from ₹521.97 Lakhs)
  • Profit/(Loss) for the period: (₹60.94 Lakhs) vs. ₹83.94 Lakhs profit in Q1 FY25
• Consolidated:
  • Revenue from operations: ₹2,344.47 Lakhs (up YoY from ₹1,012.07 Lakhs and down QoQ from ₹4,917.42 Lakhs)
  • Profit for the period: ₹500.82 Lakhs vs. (₹11.71 Lakhs) loss in Q1 FY25
• Exceptional items: Consolidated loss of ₹11.26 Lakhs in Q1 FY26; none in standalone
• Tax expense includes significant deferred tax assets in Q1 FY26 for both standalone and consolidated results
• EBITDA, margins, and EPS not explicitly disclosed

Balance Sheet / Other Financials:

• No specific updates on debt, cash reserves, or capital assets disclosed

Management Commentary:

• No management commentary or outlook provided
• No changes in accounting policies or material adjustments reported

Segment Performance:

• No segment-wise financial details disclosed
• Consolidated results include subsidiaries and associates across India, Philippines, Singapore, and Malaysia in medical ventures, healthcare innovations, and hospitality

Key Developments:

• Resignation of Independent Director Dr. Jacob Thomas effective 14 August 2025
• Appointment of M/s Nuren Lodaya & Associates as Secretarial Auditors for five years from 32nd AGM
• No acquisitions, disposals, mergers, or restructuring reported

Outlook:

• No guidance or outlook provided

Additional Notes:

• Auditor’s review reports for both standalone and consolidated results are clean with no qualifications or concerns
• Financials prepared under Ind AS 34 and comply with SEBI regulations

Summary prepared based on the unaudited standalone and consolidated Q1 FY26 results filing dated 14 August 2025.